How FTC Chair Lina Khan Became an Election Hot Topic
Posted inAntitrust Laws and Competition Issues Appointments and Executive Changes Federal Trade Commission Khan, Lina Mergers, Acquisitions and Divestitures Politics and Government Presidential Election of 2024 Regulation and Deregulation of Industry

How FTC Chair Lina Khan Became an Election Hot Topic

The Federal Trade Commission chair drew increasing political vitriol as the presidential vote neared. Her political future hangs in the balance.
Tapestry-Capri Fashion Merger Is Blocked by Judge
Posted inAntitrust Laws and Competition Issues Capri Holdings Ltd Coach Inc Decisions and Verdicts Fashion and Apparel Federal Trade Commission Handbags and Purses Kate Spade & Co Khan, Lina Mergers, Acquisitions and Divestitures Shopping and Retail Suits and Litigation (Civil) Tapestry Inc Versace, Gianni, SpA

Tapestry-Capri Fashion Merger Is Blocked by Judge

The F.T.C. had sued to halt the merger of Tapestry, the parent of Coach and Kate Spade, and Capri, the owner of Versace and Michael Kors.
Can Corporate America Help Harris Win Pennsylvania?
Posted inBanking and Financial Institutions Biden, Joseph R Jr Capital Gains Tax Corporate Taxes Cuban, Mark Harris, Kamala D internal-storyline-no Khan, Lina KKR & Co LP Lazard Ltd Presidential Election of 2024 Trump, Donald J United States Economy West, Tony (1965- )

Can Corporate America Help Harris Win Pennsylvania?

The vice president has raised huge sums and has won over many business leaders. Despite that, the presidential race remains tight in battleground states.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
Posted inCIGNA Corporation CVS Caremark Corporation Drugs (Pharmaceuticals) Drugstores Express Scripts Inc Federal Trade Commission Health Insurance and Managed Care Insulin Khan, Lina Presidential Election of 2024 Prices (Fares, Fees and Rates) Regulation and Deregulation of Industry Suits and Litigation (Civil)

F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.